Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works

Mild cognitive impairment – Beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment.

Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · see citing works

A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains

Good, C. D., Johnsrude, I. S., Ashburner, J., Henson, R. N. A., Friston, K. J., & Frackowiak, R. S. J. (2001) · NeuroImage · doi:10.1006/nimg.2001.0786 · Cited by 4,561 · see citing works

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works

Mild cognitive impairment

Gauthier, S. G., Reisberg, ‌., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,920 · see citing works

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279 · see citing works

Revising the definition of Alzheimer's disease: a new lexicon

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works

Design and construction of a realistic digital brain phantom

Collins, D. L., Zijdenbos, A. P., Kollokian, V., Sled, J. G., Kabani, N. J., Holmes, C. J., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.712135 · Cited by 1,825 · see citing works

Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410 · see citing works

Imaging β-amyloid burden in aging and dementia

Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104 · see citing works

Frequent amyloid deposition without significant cognitive impairment among the elderly

Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059 · see citing works

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · see citing works

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

Ellis, K. A., Bush, A. I., Darby, D., Fazio, D. D., Foster, J. K., Hudson, P. J., Lautenschlager, N. T., Lenzo, N. P., Martins, R. N., Maruff, P. T., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 970 · see citing works

The neuropathology of probable Alzheimer disease and mild cognitive impairment

Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935 · see citing works

Comparing predictors of conversion and decline in mild cognitive impairment

Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616 · see citing works

Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603 · see citing works

Automated model-based bias field correction of MR images of the brain

Leemput, K. V., Maes, F., Vandermeulen, D., & Suetens, P. (1999) · IEEE Transactions on Medical Imaging · doi:10.1109/42.811268 · Cited by 581 · see citing works

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476 · see citing works

Amnestic syndrome of the medial temporal type identifies prodromal AD

Sarazin, M., Berr, C., de Rotrou, J., Fabrigoule, C., Pasquier, F., Legrain, S., Michel, B. F., Puel, M., Volteau, M., Touchon, J., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000279336.36610.f7 · Cited by 464 · see citing works

Brain β-amyloid load approaches a plateau

Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406 · see citing works

APPENDIX B: PRACTICE PARAMETER: DIAGNOSIS OF DEMENTIA (AN EVIDENCE-BASED REVIEW)

(2007) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000267232.84626.41 · Cited by 390 · see citing works

A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests

Greiner, M., Sohr, D., & Göbel, P. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(95)00121-p · Cited by 370 · see citing works

Amyloid imaging in mild cognitive impairment subtypes

Wolk, D. A., Price, J. C., Saxton, J. A., Snitz, B. E., James, J. A., López, O. L., Aizenstein, H. J., Cohen, A. D., Weissfeld, L. A., Mathis, C. A., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21598 · Cited by 339 · see citing works

Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association

Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120618 · Cited by 329 · see citing works

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bbe · Cited by 243 · see citing works

β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia

Bourgeat, P., Chételat, G., Villemagne, V. L., Fripp, J., Raniga, P., Pike, K., Acosta, O., Szoeke, C., Ourselin, S., Ames, D., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918b5 · Cited by 220 · see citing works

Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study

Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188 · see citing works

A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease

Nordberg, A., Carter, S. F., Rinne, J., Drzezga, A., Brooks, D. J., Vandenberghe, R., Perani, D., Forsberg, A., Långström, B., Scheinin, N., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2237-2 · Cited by 186 · see citing works

Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant

Mormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L., & Jagust, W. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.07.098 · Cited by 158 · see citing works

Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design

van Rossum, I. A., Vos, S. J. B., Handels, R. L. H., & Visser, P. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091606 · Cited by 143 · see citing works

Relationship Between Functional and Neuropsychological Performance in Early Alzheimer Disease

Perry, R. J., & Hodges, J. R. (2000) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200001000-00001 · Cited by 109 · see citing works

Neuropathology of mild cognitive impairment

Saito, Y., & Murayama, S. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00806.x · Cited by 92 · see citing works

Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment

Lorenzi, M., Donohue, M., Paternicò, D., Scarpazza, C., Ostrowitzki, S., Blin, O. J., Irving, E. A., & Frisoni, G. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.036 · Cited by 54 · see citing works

Mild cognitive impairment

Petersen, R. C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68881-8 · Cited by 45 · see citing works

Cognitive Decline in Adults with Amnestic Mild Cognitive Impairment and High Amyloid-β: Prodromal Alzheimer's Disease?

Lim, Y. Y., Ellis, K. A., Harrington, K., Pietrzak, R. H., Gale, J., Ames, D. J., Bush, A. I., Darby, D., Martins, R. N., Masters, C. L., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121771 · Cited by 34 · see citing works

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works

Alzheimer's disease

Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works

Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future

Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988 · see citing works

Spreading of pathology in neurodegenerative diseases: a focus on human studies

Brettschneider, J., Tredici, K. D., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3887 · Cited by 790 · see citing works

The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725 · see citing works

Current state of Alzheimer’s fluid biomarkers

Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works

Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions

Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 440 · see citing works

Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment

Cheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.127 · Cited by 409 · see citing works

Age, Sex, andAPOEε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span

Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Vemuri, P., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Machulda, M. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4821 · Cited by 382 · see citing works

Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology

Ayton, S., Wang, Y., Diouf, I., Schneider, J. A., Brockman, J. D., Morris, M. C., & Bush, A. I. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0375-7 · Cited by 372 · see citing works

Fibre-specific white matter reductions in Alzheimer’s disease and mild cognitive impairment

Mito, R., Raffelt, D., Dhollander, T., Vaughan, D. N., Tournier, J.-D., Salvado, O., Brodtmann, A., Rowe, C. C., Villemagne, V. L., & Connelly, A. (2018) · Brain · doi:10.1093/brain/awx355 · Cited by 309 · see citing works

The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals

Sperling, R. A., Mormino, E. C., Schultz, A. P., Betensky, R. A., Papp, K. V., Amariglio, R. E., Hanseeuw, B. J., Buckley, R., Chhatwal, J., Hedden, T., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25395 · Cited by 286 · see citing works

Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging

Kapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, S. T., Diehl, T. C., Spangler, R. D., Tran, J., Lazaropoulos, M. P., Chawla, S., Gulyani, S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2462 · Cited by 241 · see citing works

Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads

Thurfjell, L., Lilja, J., Lundqvist, R., Buckley, C. J., Smith, A. P. L., Vandenberghe, R. R., & Sherwin, P. F. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.142109 · Cited by 224 · see citing works

Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting

Roberts, R. O., Aakre, J. A., Kremers, W. K., Vassilaki, M., Knopman, D. S., Mielke, M. M., Alhurani, R., Geda, Y. E., Machulda, M. M., Coloma, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0629 · Cited by 223 · see citing works

Current advances in digital cognitive assessment for preclinical Alzheimer's disease

Öhman, F., Hassenstab, J., Berron, D., Schöll, M., & Papp, K. V. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12217 · Cited by 214 · see citing works

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease

Lim, Y. Y., Maruff, P. T., Pietrzak, R. H., Ames, D. J., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Szoeke, C. E. I., Martins, R. N., Masters, C. L., et al. (2013) · Brain · doi:10.1093/brain/awt286 · Cited by 207 · see citing works

Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study

Burnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., Maruff, P., Salvado, O., Ames, D., Martins, R. N., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30125-9 · Cited by 207 · see citing works

Cognitive impairment and decline in cognitively normal older adults with high amyloid‐β: A meta‐analysis

Baker, J. E., Lim, Y. Y., Pietrzak, R. H., Hassenstab, J. J., Snyder, P. J., Masters, C. L., & Maruff, P. T. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.09.002 · Cited by 203 · see citing works

Dendritic spines provide cognitive resilience against <scp>A</scp> lzheimer's disease

Boros, B. D., Greathouse, K. M., Gentry, E. G., Curtis, K. A., Birchall, E. L., Gearing, M., & Herskowitz, J. H. (2017) · Annals of Neurology · doi:10.1002/ana.25049 · Cited by 198 · see citing works

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

Petersen, R. C., Wiste, H. J., Weigand, S. D., Rocca, W. A., Roberts, R. O., Mielke, M. M., Lowe, V. J., Knopman, D. S., Pankratz, V. S., Machulda, M. M., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3098 · Cited by 196 · see citing works

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals

Fandos, N., Pérez‐Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., Doecke, J., Fowler, C., Masters, C. L., Sarasa, M., et al. (2017) · Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring · doi:10.1016/j.dadm.2017.07.004 · Cited by 187 · see citing works

Amyloid blood biomarker detects Alzheimer's disease

Nabers, A., Perna, L., Lange, J., Mons, U., Schartner, J., Güldenhaupt, J., Saum, K., Janelidze, S., Holleczek, B., Rujescu, D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708763 · Cited by 185 · see citing works

Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer’s disease

Zhang, X., Mormino, E. C., Sun, N., Sperling, R. A., Sabuncu, M. R., Yeo, B. T. T., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611073113 · Cited by 178 · see citing works

Cardiovascular Disease and Alzheimer's Disease: The Heart–Brain Axis

Saeed, A., López, O., Cohen, A. D., & Reis, S. (2023) · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease · doi:10.1161/jaha.123.030780 · Cited by 138 · see citing works

Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease

Fowler, C., Rainey-Smith, S. R., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., Burnham, S. C., Bush, A. I., Chadunow, C., Collins, S., et al. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210005 · Cited by 164 · see citing works

Neuroinflammatory Processes, A1 Astrocyte Activation and Protein Aggregation in the Retina of Alzheimer’s Disease Patients, Possible Biomarkers for Early Diagnosis

Grimaldi, A., Pediconi, N., Oieni, F., Pizzarelli, R., Rosito, M., Giubettini, M., Santini, T., Limatola, C., Ruocco, G., Ragozzino, D., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00925 · Cited by 153 · see citing works

The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable

Knopman, D. S., Haeberlein, S. B., Carrillo, M. C., Hendrix, J. A., Kerchner, G., Margolin, R. A., Maruff, P. T., Miller, D. S., Tong, G., Tome, M. B., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.002 · Cited by 140 · see citing works

Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study

Pérez‐Grijalba, V., Romero, J., Pesini, P., Sarasa, L., Monleón, I., José, I. S., Arbizu, J., Martínez‐Lage, P., Munuera, J., Ruiz, A., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.41 · Cited by 135 · see citing works

Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies

Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129 · see citing works

Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline

Boyle, P. A., Yang, J., Yu, L., Leurgans, S. E., Capuano, A. W., Schneider, J. A., Wilson, R. S., & Bennett, D. A. (2016) · Brain · doi:10.1093/brain/aww341 · Cited by 129 · see citing works

The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis

Kirmess, K. M., Meyer, M. R., Holubasch, M. S., Knapik, S. S., Hu, Y., Jackson, E. N., Harpstrite, S. E., Verghese, P. B., West, T., Fogelman, I., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.05.011 · Cited by 129 · see citing works

APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer’s disease

Lim, Y. Y., Villemagne, V. L., Laws, S. M., Pietrzak, R. H., Snyder, P. J., Ames, D. J., Ellis, K. A., Harrington, K., Rembach, A., Martins, R. N., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.123 · Cited by 122 · see citing works

Genetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities

Reitz, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1002469 · Cited by 120 · see citing works

Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer’s Disease

Mormino, E. C., & Papp, K. V. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179928 · Cited by 117 · see citing works

Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study

Deters, K., Napolioni, V., Sperling, R. A., Greicius, M. D., Mayeux, R. P., Hohman, T. J., & Mormino, E. C. (2021) · Neurology · doi:10.1212/wnl.0000000000011599 · Cited by 115 · see citing works

Aβ-amyloid and Tau Imaging in Dementia

Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110 · see citing works

Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease

Johnson, P., Vandewater, L., Wilson, W. J., Maruff, P. T., Savage, G. R., Graham, P. L., Macaulay, L. S., Ellis, K. A., Szoeke, C. E. I., Martins, R. N., et al. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-s16-s11 · Cited by 110 · see citing works

Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease

Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 107 · see citing works

Comparison of ¹⁸F‐florbetaben quantification results using the standard Centiloid, MR‐based, and MR‐less CapAIBL^® approaches: Validation against histopathology

Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93 · see citing works

Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study

Ong, K. T., Villemagne, V. L., Bahar‐Fuchs, A., Lamb, F., Langdon, N., Catafau, A. M., Stephens, A. W., Seibyl, J. P., Dinkelborg, L. M., Reininger, C. B., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308094 · Cited by 100 · see citing works

Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score

Lim, Y., Snyder, P., Pietrzak, R., Ukiqi, A., Villemagne, V., Ames, D., Salvado, O., Bourgeat, P., Martins, R., Masters, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.dadm.2015.11.003 · Cited by 107 · see citing works

Dendritic spine remodeling accompanies Alzheimer's disease pathology and genetic susceptibility in cognitively normal aging

Boros, B. D., Greathouse, K. M., Gearing, M., & Herskowitz, J. H. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.003 · Cited by 90 · see citing works

Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment

Wolk, D., Sadowsky, C., Safirstein, B., Rinne, J., Duara, R., Perry, R., Agronin, M., Gámez, J. E., Shi, J., Ivanoiu, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0894 · Cited by 83 · see citing works

Association of &bgr;-Amyloid and Apolipoprotein E &egr;4 With Memory Decline in Preclinical Alzheimer Disease

Lim, Y., Kalinowski, P., Pietrzak, R., Laws, S., Burnham, S., Ames, D., Villemagne, V., Fowler, C., Rainey-Smith, S., Martins, R., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4325 · Cited by 80 · see citing works

Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing

Pietrzak, R. H., Lim, Y. Y., Ames, D. J., Harrington, K., Restrepo, C., Martins, R. N., Rembach, A., Laws, S. M., Masters, C. L., Villemagne, V. L., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.015 · Cited by 84 · see citing works

Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation

Ekblad, L. L., Johansson, J. J., Helin, S., Viitanen, M. H., Laine, H. K., Puukka, P. J., Jula, A., & Rinne, J. O. (2018) · Neurology · doi:10.1212/wnl.0000000000005214 · Cited by 84 · see citing works

Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals

van der Kall, L. M., Truong, T. H., Burnham, S. C., Doré, V., Mulligan, R. S., Bozinovski, S., Lamb, F., Bourgeat, P., Fripp, J., Schultz, S. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011222 · Cited by 84 · see citing works

Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update

Farid, K., Charidimou, A., & Baron, J. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.05.002 · Cited by 83 · see citing works

APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease

Lim, Y. Y., Villemagne, V. L., Pietrzak, R. H., Ames, D. J., Ellis, K. A., Harrington, K., Snyder, P. J., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.008 · Cited by 80 · see citing works

Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI)

Nathan, P. J., Lim, Y. Y., Abbott, R., Galluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Bartrés‐Faz, D., Didic, M., Farotti, L., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.013 · Cited by 78 · see citing works

<i>BDNF</i>Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer’s disease

Lim, Y. Y., Hassenstab, J., Cruchaga, C., Goate, A., Fagan, A. M., Benzinger, T. L. S., Maruff, P., Snyder, P. J., Masters, C. L., Allegri, R., et al. (2016) · Brain · doi:10.1093/brain/aww200 · Cited by 76 · see citing works

CenTauR: Toward a universal scale and masks for standardizing tau imaging studies

Villemagne, V. L., Leuzy, A., Bohorquez, S. M. S., Bullich, S., Shimada, H., Rowe, C. C., Bourgeat, P., Lopresti, B. J., Huang, K., Krishnadas, N., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12454 · Cited by 72 · see citing works

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Chiotis, K., Saint‐Aubert, L., Boccardi, M., Gietl, A. F., Picco, A., Varrone, A., Garibotto, V., Herholz, K., Nobili, F. M., Nordberg, A. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.012 · Cited by 75 · see citing works

Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease

Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 75 · see citing works

Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.

Schreiber, S., Landau, S., Fero, A., Schreiber, F., & Jagust, W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1633 · Cited by 83 · see citing works

Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease

Lim, Y. Y., Maruff, P. T., Schindler, R. J., Ott, B. R., Salloway, S., Yoo, D. C., Noto, R. B., Santos, C. Y., & Snyder, P. J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.07.009 · Cited by 73 · see citing works

Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias

Nasrallah, I. M., & Wolk, D. A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.141416 · Cited by 73 · see citing works

Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease

The Australian Imaging, B. A. L. (. S., Gu, B. J., Huang, X., Ou, A., Rembach, A., Fowler, C. J., Avula, P. K., Horton, A., Doecke, J. D., Villemagne, V. L., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1596-3 · Cited by 68 · see citing works

Predictive Accuracy of Amyloid Imaging for Progression From Mild Cognitive Impairment to Alzheimer Disease With Different Lengths of Follow-up

Ma, Y., Zhang, S., Li, J., Zheng, D., Guo, Y., Feng, J., & Ren, W.-D. (2014) · Medicine · doi:10.1097/md.0000000000000150 · Cited by 71 · see citing works

A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer’s Disease

Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68 · see citing works

PET molecular imaging for pathophysiological visualization in Alzheimer’s disease

Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 66 · see citing works

The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update

Hendrix, J. A., Finger, B., Weiner, M. W., Frisoni, G. B., Iwatsubo, T., Rowe, C. C., Kim, S. Y., Guinjoan, S. M., Sevlever, G. E., & Carrillo, M. C. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.008 · Cited by 65 · see citing works

Deep Learning with Neuroimaging and Genomics in Alzheimer’s Disease

Lin, E., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157911 · Cited by 64 · see citing works

Amyloid imaging: Past, present and future perspectives

Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 64 · see citing works

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

Stockmann, J., Verberk, I. M. W., Timmesfeld, N., Denz, R., Budde, B., Lange-Leifhelm, J., Scheltens, P., van der Flier, W. M., Nabers, A., Teunissen, C. E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00738-8 · Cited by 62 · see citing works

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit

Molinuevo, J. L., Camı́, J., Carné, X., Carrillo, M. C., Georges, J., Isaac, M., Khachaturian, Z. S., Kim, S. Y. H., Morris, J. C., Pasquier, F., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.009 · Cited by 60 · see citing works

Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer’s disease

Shah, T. M., Gupta, S. M., Chatterjee, P., Campbell, M., & Martins, R. N. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.251 · Cited by 62 · see citing works

Secondary prevention of Alzheimer’s dementia: neuroimaging contributions

ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 60 · see citing works

The Full Spectrum of Alzheimer’s Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes

de la Monte, S. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_4 · Cited by 59 · see citing works

Utility of an Alzheimer’s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer’s Disease: A Prospective Longitudinal Study

Porter, T., Burnham, S. C., Milicic, L., Savage, G. R., Maruff, P. T., Lim, Y. Y., Li, Q.-X., Ames, D. J., Masters, C. L., Rainey‐Smith, S. R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180713 · Cited by 56 · see citing works

Biosensors on the road to early diagnostic and surveillance of Alzheimer's disease

Carneiro, P., Morais, S., & Pereira, M. D. C. (2020) · Talanta · doi:10.1016/j.talanta.2019.120700 · Cited by 58 · see citing works

Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk

Jack, C. R., Therneau, T. M., Lundt, E. S., Wiste, H. J., Mielke, M. M., Knopman, D. S., Graff‐Radford, J., Lowe, V. J., Vemuri, P., Schwarz, C. G., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac017 · Cited by 55 · see citing works

Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease

Samaroo, A. H., Amariglio, R. E., Burnham, S. C., Sparks, P., Properzi, M. J., Schultz, A. P., Buckley, R. F., Johnson, K. A., Sperling, R. A., Rentz, D. M., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12132 · Cited by 49 · see citing works

Physical Activity in Preventing Alzheimer’s Disease and Cognitive Decline: A Narrative Review

Brini, S., Sohrabi, H. R., Peiffer, J. J., Karrasch, M., Hämäläinen, H., Martins, R. N., & Fairchild, T. J. (2017) · Sports Medicine · doi:10.1007/s40279-017-0787-y · Cited by 53 · see citing works

Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography

Brown, B. M., Rainey‐Smith, S. R., Doré, V., Peiffer, J. J., Burnham, S. C., Laws, S. M., Taddei, K., Ames, D. J., Masters, C. L., Rowe, C. C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170998 · Cited by 52 · see citing works

Molecular Imaging Approaches in Dementia

Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A. K., & van Berckel, B. N. M. (2021) · Radiology · doi:10.1148/radiol.2020200028 · Cited by 52 · see citing works

Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying β-amyloid pathology

Diouf, I., Fazlollahi, A., Bush, A. I., & Ayton, S. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.010 · Cited by 72 · see citing works

Aβ and tau structure‐based biomarkers for a blood‐ and CSF‐based two‐step recruitment strategy to identify patients with dementia due to Alzheimer's disease

Nabers, A., Hafermann, H., Wiltfang, J., & Gerwert, K. B. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.008 · Cited by 49 · see citing works

Neuroimaging biomarkers in Alzheimer’s disease and other dementias

Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 48 · see citing works

The relevance of beta-amyloid on markers of Alzheimer’s disease in clinically normal individuals and factors that influence these associations

Mormino, E. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9267-4 · Cited by 44 · see citing works

Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI.

Lim, Y., Pietrzak, R., Bourgeat, P., Ames, D., Ellis, K., Rembach, A., Harrington, K., Salvado, O., Martins, R., Snyder, P., et al. (2015) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acu068 · Cited by 53 · see citing works

Explainable machine learning aggregates polygenic risk scores and electronic health records for Alzheimer’s disease prediction

Gao, X. R., Chiariglione, M., Qin, K., Nuytemans, K., Scharre, D. W., Li, Y.-J., & Martin, E. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-27551-1 · Cited by 45 · see citing works

β-amyloid: The known unknowns

Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45 · see citing works

Amyloid PET imaging in clinical practice

Kolanko, M., Win, Z., Loreto, F., Patel, N., Carswell, C. J., Gontsarova, A., Perry, R. J., & Malhotra, P. (2020) · Practical Neurology · doi:10.1136/practneurol-2019-002468 · Cited by 45 · see citing works

A Modified Bio-Inspired Optimizer with Capsule Network for Diagnosis of Alzheimer Disease

Ganesan, P., Ramesh, G. P., Puttamdappa, C., & Yarlagadda, A. (2024) · Applied Sciences · doi:10.3390/app14156798 · Cited by 40 · see citing works

Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months

Thai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D. J., Ellis, K. A., Rainey‐Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139082 · Cited by 39 · see citing works

Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice

Guerra, U. P., Nobili, F. M., Padovani, A., Perani, D., Pupi, A., Sorbi, S., & Trabucchi, M. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2079-3 · Cited by 38 · see citing works

Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β-amyloid pathology

Diouf, I., Bush, A. I., & Ayton, S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104810 · Cited by 38 · see citing works

Aβ-related memory decline in APOE ε4 noncarriers

Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Porter, T., Ames, D. J., Fowler, C. J., Rainey‐Smith, S. R., Snyder, P. J., Martins, R. N., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002604 · Cited by 37 · see citing works

KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden

Porter, T., Burnham, S. C., Doré, V., Savage, G. R., Bourgeat, P., Begemann, K., Milicic, L., Ames, D. J., Bush, A. I., Maruff, P. T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20513-y · Cited by 37 · see citing works

Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract

Chu, W. T., Wang, W., Záborszky, L., Golde, T. E., DeKosky, S. T., Duara, R., Loewenstein, D., Adjouadi, M., Coombes, S. A., & Vaillancourt, D. E. (2021) · Neurology · doi:10.1212/wnl.0000000000013206 · Cited by 36 · see citing works

In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data

Mito, R., Dhollander, T., Xia, Y., Raffelt, D. A., Salvado, O., Churilov, L. P., Rowe, C. C., Brodtmann, A. G., Villemagne, V. L., & Connelly, A. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102479 · Cited by 37 · see citing works

The role of positron emission tomography imaging in understanding Alzheimer’s disease

Barthel, H., Seibyl, J. P., & Sabri, O. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1023296 · Cited by 34 · see citing works

The Healthy Brain Project: An Online Platform for the Recruitment, Assessment, and Monitoring of Middle-Aged Adults at Risk of Developing Alzheimer’s Disease

Lim, Y. Y., Yassi, N., Bransby, L., Properzi, M. J., & Buckley, R. F. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181139 · Cited by 34 · see citing works

Disrupted topology of the resting state structural connectome in middle-aged APOE ε4 carriers

Korthauer, L. E., Zhan, L., Ajilore, O., Leow, A., & Driscoll, I. F. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.05.052 · Cited by 32 · see citing works

Combining hippocampal volume metrics to better understand Alzheimer’s disease progression in at-risk individuals

McRae‐McKee, K., Evans, S., Hadjichrysanthou, C., Wong, M. M., de Wolf, F., & Anderson, R. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-42632-w · Cited by 31 · see citing works

Predicting Alzheimer disease from a blood-based biomarker profile

Burnham, S. C., Rowe, C. C., Baker, D., Bush, A. I., Doecke, J. D., Faux, N. G., Laws, S. M., Martins, R. N., Maruff, P. T., Macaulay, S. L., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003094 · Cited by 30 · see citing works

Neuropsychology and neuroimaging profiles of amyloid‐positive versus amyloid‐negative amnestic mild cognitive impairment patients

Tomadesso, C., Sayette, V. D. L., de Florès, R., Bourgeat, P., Villemagne, V. L., Egret, S., Eustache, F., & Chételat, G. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.02.008 · Cited by 30 · see citing works

Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment

Kandel, B. M., Avants, B., Gee, J. C., Arnold, S. E., Wolk, D. A., & Initiative, A. D. N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142943 · Cited by 29 · see citing works

O4–07–01: Biomarker‐based prediction of cognitive decline in 270 nondemented older individuals: Three‐year follow‐up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL)

Rowe, C. C., Ames, D. J., Ellis, K. A., Bourgeat, P., Brown, B. M., Salvado, O., Szoeke, C. E. I., Woodward, M., Macaulay, L. S., Maruff, P. T., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.371

IC‐P‐004: Biomarker‐based prediction of cognitive decline in 270 nondemented older individuals: Three‐year follow‐up results from the Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL)

Rowe, C. C., Ames, D. J., Ellis, K. A., Bourgeat, P., Brown, B. M., Salvado, O., Szoeke, C. E. I., Woodward, M., Macaulay, L. S., Maruff, P. T., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.005 · Cited by 1 · see citing works

O1–10–04: Amyloid‐positive MCI: Predicting progression to dementia

Chertkow, H. M., Whitehead, V., & Nikelski, J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.107

Relationship between amyloid-β positivity and progression to mild cognitive impairment or dementia over 8 years in cognitively normal older adults

Dang, C., Harrington, K. D., Lim, Y. Y., Ames, D., Hassenstab, J., Laws, S. M., Yassi, N., Hickey, M., Rainey-Smith, S., Robertson, J., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180507 · Cited by 31 · see citing works

P3‐168: Progression rates from mild cognitive impairment to dementia by biomarker and memory thresholds

Barker, W., Greig‐Custo, M. T., Rodriquez, R., Loewenstein, D., Adjouadi, M., Goryawala, M., Zhou, Q., & Duara, R. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1539